tbuckley/cabot-search huggingface dataset:
AT-09TREATMENT OF ATYPICAL TERATOID RHABDOID TUMORS (ATRT) OF THE CENTRAL NERVOUS SYSTEM WITH SURGERY, INTENSIVE CHEMOTHERAPY, AND 3-D CONFORMAL RADIATION (ACNS0333). A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Authors: Alyssa Reddy, Doug Strother, Alexander Judkins, Mark Krailo, Yun Gao, James Douglas, Anita Mahajan, Victor Lewis, Claire Mazewski, Fred Laningham, Ian Pollack, Amar Gajjar, Jaclyn Biegel
Journal: Neuro-Oncology (2016)
Non-residents with unpaid NHS bills can be reported to Home Office, Court of Appeal rules
Authors: Clare Dyer
Journal: BMJ (2015)

UK government rules imposing immigration sanctions on non-residents who owe the NHS at least £1000 for treatment are lawful, the Court of Appeal has ruled.

Rules imposed in 2011 require NHS trusts to report non-residents to the Department of Health over unpaid treatment bills totalling £1000 or more and require the department to pass this information to the Home Office. Immigration rules provide that people listed as having outstanding bills will normally be turned down if they …
Acute Cholecystitis
Authors: Sharon Parmet, Cassio Lynm, Richard M. Glass
Journal: JAMA (2003)

Acute CholecystitisC holecystitis is inflammation of the gallbladder, a small pear-shaped organ in the upper right area of the abdomen.The gallbladder holds bile produced by the liver.The bile is released into the small intestine where it aids in digestion, especially the absorption of fats.If the gallbladder is removed, that function is performed directly by the liver.In many cases of acute cholecystitis, gallstones (solid lumps formed by substances found in the gallbladder) block the bile ducts (tubes that allow bile to pass from the gallbladder into the small intestine).Bile builds up and can push on the walls of the gallbladder, causing inflammation.Other causes of acute cholecystitis include infection, trauma, diabetes, or blockage of the bile ducts due to a tumor.The January 1, 2003, issue of JAMA includes an article about diagnosing acute cholecystitis.
Neurobiological vulnerability to low-dose amphetamine psychosis
Authors: M S Gold, M B Bowers
Journal: American Journal of Psychiatry (1978)

The authors present a case to illustrate a model of drug-induced psychosis wherein the drug acts as if it fits with some neurobiological predisposition in the patient. Patients with a good interpersonal developmental history but extreme sensitivity to a psychotomimetic drug may provide a model for neurobiological vulnerability to psychosis.
G Protein–Coupled Receptor-G–Protein βγ–Subunit Signaling Mediates Renal Dysfunction and Fibrosis in Heart Failure
Authors: Fadia A. Kamal, Joshua G. Travers, Allison E. Schafer, Qing Ma, Prasad Devarajan, Burns C. Blaxall
Journal: Journal of the American Society of Nephrology (2016)

Development of CKD secondary to chronic heart failure (CHF), known as cardiorenal syndrome type 2 (CRS2), clinically associates with organ failure and reduced survival. Heart and kidney damage in CRS2 results predominantly from chronic stimulation of G protein–coupled receptors (GPCRs), including adrenergic and endothelin (ET) receptors, after elevated neurohormonal signaling of the sympathetic nervous system and the downstream ET system, respectively. Although we and others have shown that chronic GPCR stimulation and the consequent upregulated interaction between the G–protein βγ –subunit (G βγ ), GPCR-kinase 2, and β -arrestin are central to various cardiovascular diseases, the role of such alterations in kidney diseases remains largely unknown. We investigated the possible salutary effect of renal GPCR–G βγ inhibition in CKD developed in a clinically relevant murine model of nonischemic hypertrophic CHF, transverse aortic constriction (TAC). By 12 weeks after TAC, mice developed CKD secondary to CHF associated with elevated renal GPCR–G βγ signaling and ET system expression. Notably, systemic pharmacologic G βγ inhibition by gallein, which we previously showed alleviates CHF in this model, attenuated these pathologic renal changes. To investigate a direct effect of gallein on the kidney, we used a bilateral ischemia-reperfusion AKI mouse model, in which gallein attenuated renal dysfunction, tissue damage, fibrosis, inflammation, and ET system activation. Furthermore, in vitro studies showed a key role for ET receptor–G βγ signaling in pathologic fibroblast activation. Overall, our data support a direct role for GPCR-G βγ in AKI and suggest GPCR-G βγ inhibition as a novel therapeutic approach for treating CRS2 and AKI.
Preventing overuse shoulder injuries among throwing athletes: a cluster-randomised controlled trial in 660 elite handball players
Authors: Stig Haugsboe Andersson, Roald Bahr, Benjamin Clarsen, Grethe Myklebust
Journal: British Journal of Sports Medicine (2016)

Background Shoulder problems are highly prevalent among elite handball players. Reduced glenohumeral rotation, external rotation weakness and scapula dyskinesis have been identified as risk factors. Aim Evaluate the effect of an exercise programme designed to reduce the prevalence of shoulder problems in elite handball. Methods 45 elite handball teams (22 female teams, 23 male teams, 660 players) were cluster randomised (22 teams, 331 players in the intervention group, 23 teams, 329 players in the control group) and followed for 1 competitive season (7 months). The Oslo Sports Trauma Research Center (OSTRC) Shoulder Injury Prevention Programme, an exercise programme to increase glenohumeral internal rotation, external rotation strength and scapular muscle strength, as well as improve kinetic chain and thoracic mobility, was delivered by coaches and captains 3 times per week as a part of the handball warm-up. The main outcome measures, prevalence of shoulder problems and substantial shoulder problems, were measured monthly. Results The average prevalence of shoulder problems during the season was 17% (95% CI 16% to 19%) in the intervention group and 23% (95% CI 21% to 26%) in the control group (mean difference 6%). The average prevalence of substantial shoulder problems was 5% (95% CI 4% to 6%) in the intervention group and 8% (95% CI 7% to 9%) in the control group (mean difference 3%). Using generalised estimating equation models, a 28% lower risk of shoulder problems (OR 0.72, 95% CI 0.52 to 0.98, p=0.038) and 22% lower risk of substantial shoulder problems (OR 0.78, 95% CI 0.53 to 1.16, p=0.23) were observed in the intervention group compared with the control group. Conclusions The OSTRC Shoulder Injury Prevention Programme reduced the prevalence of shoulder problems in elite handball and should be included as a part of the warm-up. Trial registration number ISRCTN96217107.
Medicare’s Bundled Payment Program and Health Care Utilization
Authors: William B. Weeks
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Arsenic Binding to RBCC Domain Modulates Oncogenic PML-RARa and Wild-Type PML as a Key Molecular Mechanism of Arsenic Trioxide Treatment for APL.
Authors: Xiaowei Zhang, Xiaojing Yan, Feifei Yang, Ziren Zhou, Ziyu Wu, Hongbin Sun, Wenxue Liang, Aixin Song, Qiuhua Huang, Guangbiao Zhou, Jianhua Tong, Yan Zhang, Jihui Wu, Hongyu Hu, Saijuan Chen, Zhu Chen
Journal: Blood (2009)
Chromocenters Resembling Sex Chromatin in Human Tissue-Culture Cell Lines
Authors: Sara H. Dewitt, Alan S. Rabson, Frances Y. Legallais, Pasco R. Del Vecchio, Richard A. Malmgren
Journal: JNCI Journal of the National Cancer Institute (1959)

Chromocenters resembling sex chromatin were studied in 12 human tissue-culture cell lines derived from both normal tissues and malignant tumors. All of these cell lines had low counts, and there was no correlation of the sex of the donor of the tissue from which the cell strain was derived with counts of chromocenters resembling sex chromatin of the cell-culture preparations. There was no significant difference in the counts in cell lines derived from normal human tissues and those derived from malignant tumors. This is in accord with the findings of others that cell strains derived from normal tissue are morphologically and biochemically similar to those derived from malignant tumors.
Course of Magnetic Resonance Imaging-Detected Inflammation and Structural Lesions in the Sacroiliac Joints of Patients in the Randomized, Double-Blind, Placebo-Controlled Danish Multicenter Study of Adalimumab in Spondyloarthritis, as Assessed by the Berl
Authors: Susanne J. Pedersen, Denis Poddubnyy, Inge J. Sørensen, Anne‐Gitte Loft, Jens S. Hindrup, Gorm Thamsborg, Karsten Asmussen, Oliver Hendricks, Jesper Nørregaard, Anne‐Dorthe Piil, Jakob M. Møller, Anne‐Grethe Jurik, Lone Balding, Robert G. Lambert, Joachim Sieper, Mikkel Østergaard
Journal: Arthritis & Rheumatology (2015)

To investigate changes in magnetic resonance imaging (MRI)-assessed inflammation and structural lesions in the sacroiliac (SI) joints during treatment with adalimumab versus placebo.In a 48-week double-blind, placebo-controlled trial, 52 patients with spondyloarthritis were randomized to receive subcutaneous injections of either adalimumab 40 mg (n = 25) or placebo (n = 27) every other week for 12 weeks. Patients in the adalimumab group continued to receive and patients in the placebo group were switched to adalimumab 40 mg every other week for an additional 12 weeks. MRI of the SI joints was performed at weeks 0, 12, 24, and 48, and the images were assessed independently in a blinded manner using the modified Berlin and the Spondyloarthritis Research Consortium of Canada (SPARCC) MRI scores for inflammation and structural lesions of the SI joints.At baseline, 56% of the adalimumab group and ∼72% of the placebo group had an MRI-assessed inflammation score of ≥1. Among the patients with inflammation at baseline, the mean percent reductions in MRI scores for inflammation from week 0 to 12 were greater in the adalimumab group compared with the placebo group (Berlin method, -62% versus -5%; SPARCC method, -58% versus -12% [both P < 0.04]). Furthermore, the mean SPARCC erosion score decreased (-0.6) and the SPARCC backfill score increased (+0.8) in the adalimumab group from week 0 to week 12. From week 12 to week 24, larger absolute reductions in the Berlin/SPARCC inflammation scores and the SPARCC erosion score and larger increases in the Berlin/SPARCC fatty lesion scores were seen in the placebo group compared with the adalimumab group. In univariate regression analyses (analysis of covariance) and multivariate stepwise regression analyses, treatment with adalimumab was independently associated with regression of the SPARCC erosion score from week 0 to 12 but not with changes in the other types of MRI lesions.Significant changes in the Berlin and SPARCC MRI-assessed inflammation scores and in the SPARCC MRI-assessed erosion scores occurred within 12 weeks after initiation of adalimumab. Tumor necrosis factor inhibitor treatment was associated with resolution of erosions and the development of backfill.
Effect of Enforced Activity Stress on the Development of Experimental Papillomas in Mice&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: J A STERN, G WINOKUR, D T GRAHAM, R LEFTON
Journal: JNCI Journal of the National Cancer Institute (1959)

The experimental stress of enforced activity was shown to be related to a significant enhancement of papilloma development and death rate. Stress initiated concurrently with application of the carcinogen exerted a more profound effect than was observed in pre-stressed animals.
LG-51RETROSPECTIVE ANALYSIS OF PATHOLOGICALLY DIAGNOSED LOW-GRADE GLIOMA: EXPERIENCE OF A SINGLE INSTITUTE
Authors: Yoshiko Nakano, Kai Yamasaki, Yuko Fukushima, Takeshi Inoue, Chika Nitani, Keiko Okada, Hiroyuki Fujisaki, Yuko Osugi, Noritsugu Kunihiro, Kenichi Ishibashi, Yasuhiro Matsusaka, Koichi Ichimura, Hiroaki Sakamoto, Junichi Hara
Journal: Neuro-Oncology (2016)
MB-04A NOVEL GERMLINE MUTATION IN ALK GENE (M1199L) IDENTYFIED IN THE WNT TYPE OF MEDULLOBLASTOMA
Authors: Joanna Trubicka, Malgorzata Szperl, Wieslawa Grajkowska, Agnieszka Karkucinska-Wieckowska, Magdalena Tarasinska, Katarzyna Falana, Marta Perek-Polnik, Bozenna Dembowska-Baginska, Maria Lastowska
Journal: Neuro-Oncology (2016)
The Early Warning and Response System for communicable diseases in the EU: an overview from 1999 to 2005
Authors: P Guglielmetti, D Coulombier, G G Thinus, F Van Loock, S Schreck
Journal: Eurosurveillance (2006)

Under Decision 2119/98/EC of the European Parliament and of the Council, a network for epidemiological surveillance and control of communicable diseases in the Community was set up in 1998. One pillar of Decision 2119/98/EC is the early warning and response system (EWRS). The main objective of the network is to establish permanent communication between European Union (EU) Member States' public health authorities, which are responsible for determining the measures required to control communicable disease-related events. Since 1998, a web based informatics tool has been developed in order to allow information to be shared between the relevant public health authorities. Between 1998 and December 2005, a total of 583 messages were circulated through the EWRS, notifying 396 events. The information shared through the system helped to coordinate public health measures in the EU. However, only few events prompted specific measures at Community level and most of them were controlled with public health measures applied at national level. Major events (such as the Severe Acute Respiratory Syndrome) and the results of simulation exercises prompted the Commission to upgrade the informatics system on the basis of user needs. Since 1 May 2004 the 10 newest Member States have provided information under the current legislation and since April 2005 the European Centre for Disease Prevention and Control (ECDC) is part of the system. Future developments will include a link between the existing EWRS and the communication platform currently developed by the ECDC.
MB-34CIRCULATING microRNAs IN GROUP 4 MEDULLOBLASTOMA PATIENTS
Authors: Evelina Miele, Vincenzo Alfano, Zein Mersini Besharat, Giuseppina Catanzaro, Angela Mastronuzzi, Andrea Carai, Agnese Po, Antonella Cacchione, Luana Abballe, Felice Giangaspero, Franco Locatelli, Elisabetta Ferretti
Journal: Neuro-Oncology (2016)
Case 33-1978
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, William E. Strole, James J. Galdabini
Journal: New England Journal of Medicine (1978)

Presentation of CaseA 63-year-old woman was admitted to the hospital because of diarrhea.There was a long history of degenerative arthritis of the left hip. Two years before admission pain became so severe that the patient was unable to walk and began a bed-and-chair existence. A cutaneous ulcer on the left ankle was treated with a skin graft. A sacral decubitus ulcer developed.Five weeks before entry she was brought to the hospital in coma. There was no history of diabetes mellitus or thyroid disease. Examination revealed that she was febrile. The hair was dry and brittle; the thyroid . . .
THE JOURNEY TO MOSCOW.
Authors: M POWELL
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Success or failure: psychotherapeutic considerations for women in conflict
Authors: C C Nadelson, M T Notman, M B Bennett
Journal: American Journal of Psychiatry (1978)

The authors describe conflicts experienced by women who request therapeutic intervention because of symptoms of depression, anxiety, marital discord, difficulty in asserting themselves, or inability to complete work that would lead to advancement. They discuss the developmentally based difficulties experienced by women in making career choices, advancing their careers, and facing midlife issues. The therapist who deals with such patients must be aware of reality-based factors and of his or her own values and attitudes as they influence choice of therapeutic approach.
The Smart Drug Delivery System and Its Clinical Potential
Authors: Dong Liu, Fang Yang, Fei Xiong, Ning Gu
Journal: Theranostics (2016)

With the unprecedented progresses of biomedical nanotechnology during the past few decades, conventional drug delivery systems (DDSs) have been involved into smart DDSs with stimuli-responsive characteristics. Benefiting from the response to specific internal or external triggers, those well-defined nanoplatforms can increase the drug targeting efficacy, in the meantime, reduce side effects/toxicities of payloads, which are key factors for improving patient compliance. In academic field, variety of smart DDSs have been abundantly demonstrated for various intriguing systems, such as stimuli-responsive polymeric nanoparticles, liposomes, metals/metal oxides, and exosomes. However, these nanoplatforms are lack of standardized manufacturing method, toxicity assessment experience, and clear relevance between the pre-clinical and clinical studies, resulting in the huge difficulties to obtain regulatory and ethics approval. Therefore, such relatively complex stimulus-sensitive nano-DDSs are not currently approved for clinical use. In this review, we highlight the recent advances of smart nanoplatforms for targeting drug delivery. Furthermore, the clinical translation obstacles faced by these smart nanoplatforms have been reviewed and discussed. We also present the future directions and perspectives of stimuli-sensitive DDS in clinical applications.
Developing more open and equitable relationships with industry to improve advancements in clinical research in dermatology
Authors: M. Campa, C. Ryan, A. Menter
Journal: British Journal of Dermatology (2016)

Relationships between physicians, scientists, and the pharmaceutical industry can be complicated by conflicts of interest. Honest and equitable relationships, however, are essential to the advancement of dermatologic clinical research. Several factors can increase transparency in clinical trials including preregistration of clinical trials, reporting of all data produced from clinical trials, non-industry ownership of clinical trial data, clarity of statistical methods and publication of both positive and negative results. Through collaborative, scientifically rigorous studies, physicians and industry can achieve significant advances in dermatologic care.
Emerging Indications for Interventional Endoscopic Ultrasonography
Authors: M S Bhutani
Journal: Endoscopy (2003)

Remarkable advances have been made in endoscopic ultrasound in recent years with endoscopic ultrasound moving from a pure diagnostic procedure to an interventional modality. Endoscopic ultrasound (EUS) guided fine needle aspiration has established its clinical impact in sampling lesions within and in close proximity to the gastrointestinal tract in multiple locations above and below the diaphragm [1] [2] [3] [4] [5]. The development of echoendoscopes that allow real time visualization of a needle along its length has circumvented the earlier problem of EUS not being able to provide a tissue diagnosis and has opened up a host of possibilities of different interventional techniques under EUS guidance. Linear array echoendoscopes are able to visualize a needle along its long axis as well as ultrasonically monitor its depth of penetration. This has resulted in fine needle aspiration under EUS guidance becoming a standard procedure for sampling lymph nodes, pancreatic masses and submucosal lesions [1] [2] [3] [4] [5]. Many other possibilities exist for utilization of EUS as an interventional procedure. This paper will review some recent, novel, emerging and ongoing applications/possibilities with interventional EUS.
Influenza A(H1N1)2009 in the French Pacific territories: assessment of the epidemic wave during the austral winter
Authors: Philippe Barboza, Claire Baudon, Laurence Chérié-Challine, Marc Gastellu-Etchegorry, Juliette Gueguen, Guy La Ruche, Jean-Paul Grangeon, Sylvie Laumond-Barny, Martine Noël, Anne Pfannstiel, Antonio Chee-Ayee, Elise Daudens, Eddy Frogier, Bernard Le, Henri-Pierre Mallet, Jean-Paul Pescheux, Hervé Vergeaud, Stéphane Lastère, Elisabeth Dutaut, Jean-François Yvon
Journal: Clinical Microbiology and Infection (2010)
Activity of C-7 Substituted Cyclic Acetal Derivatives of Mitomycin C and Porfiromycin Against Hypoxic and Oxygenated EMT6 Carcinoma Cells <i>In Vitro</i> and <i>In Vivo</i>
Authors: S Rockwell, S R Keyes, R Loomis, M Kelley, D M Vyas, H Wong, T W Doyle, A C Sartorelli
Journal: Cancer Communications (1991)

A series of cyclic acetal derivatives of mitomycin C (MC) and porfiromycin (POR) were tested for their ability to kill hypoxic and oxygenated EMT6 tumor cells. Amino methyl acetal and thioacetal substitutions at C-7 of MC and POR dramatically increased the cytotoxicity of the compounds to hypoxic EMT6 tumor cells in vitro but had little effect on the aerobic toxicities. In contrast, a methyl substitution at N1a markedly decreased the aerobic cytotoxicities of the compounds but did not alter the hypoxic cytotoxicities. The POR acetal, BMY-42355, had the largest differential between hypoxic and aerobic cytotoxicities yet observed among MC analogs. Preliminary studies in mice showed that BMY-42355 had good antineoplastic activity when used alone or in combination with radiation and was less toxic than POR; the therapeutic ratio of this compound in these initial studies was higher than those of either MC or POR.